Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adapalene/clindamycin - Lee's Pharmaceutical

Drug Profile

Adapalene/clindamycin - Lee's Pharmaceutical

Alternative Names: Adapalene-Clindamycin combination gel - Lee's Pharmaceutical; Clindamycin/adapalene - Lee's Pharmaceutical; ZK-008

Latest Information Update: 02 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lee's Pharmaceutical
  • Class Adamantanes; Antiacnes; Antibacterials; Keratolytics; Lincosamides; Naphthalenes; Pyrrolidines; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Acne vulgaris

Most Recent Events

  • 02 Mar 2021 Phase-III development is ongoing for Acne vulgaris in China
  • 14 Apr 2020 Lee's Pharmaceutical announces intention to submit NDA for Acne vulgaris in China
  • 07 Apr 2020 Lee's Pharmaceutical completes a phase-III trials in Acne vulgaris in China (Topical) (NCT03615768)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top